Hogan Lovells has welcomed back Tao Xin as a partner at its Washington office, strengthening the firm’s global pharmaceuticals and biotechnology practice.
Before rejoining, he was chair of the US healthcare and life sciences regulatory practice at Baker McKenzie.
“Xin’s return comes at the perfect time,” said David Fox, practice area leader for pharmaceuticals and biotechnology at Hogan Lovells, in a press release. “His experience guiding Chinese companies pursuing global expansion through the unique regulatory challenges they face complements our existing work and will aid our clients immensely.”
Tao has nearly 15 years of experience and has been a partner at Baker McKenzie’s Washington office since early 2023. Earlier, he spent almost a decade at Hogan Lovells, where he was promoted from senior associate to counsel. He began his career at Keller and Heckman, based in Washington.
He advises life sciences, food, consumer platform and technology companies as well as investors on global compliance and transactions, particularly those headquartered in China or expanding their business across the Asia-Pacific region.
Notably, alongside his legal background, Tao holds a bachelor’s degree in biotechnology and a master’s degree in biochemistry from institutions in China and the US, respectively. This scientific research background underpins his ability to offer practical guidance on complex regulatory issues in these sectors.
He also assists clients in navigating legal, commercial and cultural challenges in cross-border collaborations and strategic transactions. His experience includes representing international companies in high-stakes US government investigations, including proceedings involving the US Congress, the US Department of Justice and the US Food and Drug Administration, covering product safety, regulatory compliance and national security issues.
